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 Chapter 14 
 Food Allergies: Novel Mechanisms and Therapeutic 
Perspectives 
 Margherita  Di  Costanzo ,  Lorella  Paparo ,  Linda  Cosenza ,  Carmen  Di  Scala , 
 Rita  Nocerino ,  Rosita  Aitoro , and  Roberto  Berni  Canani 
 Abstract 
 Childhood food allergy (FA) rates have rapidly increased with signifi cant direct medical costs for the health 
care system and even larger costs for the families with a food-allergic child. The possible causes of food 
allergy become the target of intense scrutiny in recent years. Increasing evidence underline the importance 
in early life of gut microbiome in the development of allergic diseases. There are a range of factors in the 
modern environment that may be associated with changes to both the gut microbiome and risk of FA, such 
as mode of delivery, antibiotic exposure, infant feeding practices, farming environment, and country of 
origin. Knowledge of the relationship between early life gut microbiome and allergic diseases may facilitate 
development of novel preventive and treatment strategies. Based on our current knowledge, there are no 
currently available approved therapies for food allergy. More studies are needed to evaluate the safety and 
effi cacy of allergen-specifi c and allergen-nonspecifi c approaches, as well as combination approaches. 
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1  Introduction 
 Food allergy (FA) is a major health issue in Western countries with 
a substantial effect on quality of life of both patients and their rela-
tives. On the basis of numerous studies, food allergy likely affects 
nearly 5 % of adults and 8 % of children, with growing evidence of 
an increase in prevalence [ 1 ]. Although any food can provoke a 
reaction, relatively few foods are responsible for the vast majority 
of signifi cant food induced allergic reactions: cow’s milk (2.2 %), 
peanuts (1.8 %), and tree nuts (1.7 %) are the most common aller-
gens in children, and shellfi sh (1.9 %), fruits (1.6 %), and vegeta-
bles (1.3 %) are the most common allergens in adults. Recent 
publications focusing on peanut allergy indicated increases with a 
doubling (UK) or tripling (USA) in diagnoses [ 2 ,  3 ]. In general, 
childhood FA to milk, egg, wheat, or soy typically resolves during 
childhood, whereas allergies to peanut, tree nuts, fi sh, and shellfi sh 
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are persistent. However during the last decade, a changing pattern 
in FA was observed with an increased prevalence, severity of clini-
cal manifestations, and risk of persistence until later ages in Western 
countries [ 4 ]. Over the last 20 years rates of potentially life- 
threatening reactions to food (anaphylaxis) have steadily risen in 
the developed world [ 5 ]. For these reasons, there is a strong need 
for an expansion of pre clinical research to improve understanding 
of the mechanisms and to develop novel effective strategies to pre-
vent and treat FA. 
2  New Insights into the Pathogenesis of Food Allergy 
 There is a complex interplay of environmental infl uence and genet-
ics that underlie the immunopathogenesis of food allergy and the 
manifestations of various food-induced allergic disorders. The gut 
microbiota is emerging as a crucial “internal” environmental expo-
sure [ 6 ]. We briefl y summarize what are the evidences that demon-
strate an association between microbial exposure in early life and 
the development of food allergy. 
 Microbial gut colonization begins after birth and this process 
is affected by the newborn infant’s gestational age, mode of deliv-
ery and fi rst feeding strategies. The colonizing bacteria originate 
mainly from the mother’s gut and vaginal tract [ 7 ]. After delivery, 
breast feeding continues to enhance the original inoculum by the 
introduction of specifi c lactic acid bacteria, Bifi dobacteria, and 
other bacteria from the mother’s skin. These bacteria set the basis 
for gut microbiota development and modulation. An imbalance in 
the compositional confi guration of the gut microbiota, dysbiosis, 
alters the host-microbiota homeostasis, which is a requisite for the 
development and function of immune cells in the gut associated 
lymphoid tissue. The importance of this reciprocal regulation of 
the microbiota and immune system culminates in early infancy, 
when the balance between homeostasis and infl ammation pro-
grams later disease risk. In particular, early exposure to commensal 
bacteria plays a crucial role in Th1/Th2 polarization and proper 
immune regulatory mechanisms. Germ free animals do not develop 
oral  tolerance and maintained a Th2 type immune response to 
orally administered ovalbumin. This could be corrected by the 
reconstitution of the microbiota at the neonatal stages, but not any 
reconstitution implemented at a later ages [ 8 ]. These fi ndings doc-
umented a decisive role of the gut microbiota for the acquisition of 
food oral tolerance in early life. Exposure to a normal intestinal 
microfl ora in early life allows for a change in the lymphocyte Th1/
lymphocyte Th2 balance, favoring a Th1 cell response [ 9 ], while 
an imbalance in the compositional confi guration of the gut 
 microbiota, dysbiosis, alters the host-microbiota homeostasis, 
producing a shift of the Th1/Th2 cytokine balance toward a Th2 
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response and a consequent activation of Th2 cytokines with an 
increased production of immunoglobulin E [ 10 ]. Imbalance in 
intestinal microbiota composition has been documented in patients 
with food allergy [ 11 ]. It was recently found that clostridia strains 
promote the development of  regul atory T cells in the intestine, 
and when a mix of  human clostridia strains were administered to 
mice, they could suppress the development of food allergy [ 12 , 
 13 ]. Recently, a new link between dysbiosis and food allergy devel-
opment has been provided. Maternal use of antibiotics before and 
during pregnancy was associated with an increased risk of cow’s 
milk allergy in the offspring and the risk of cow’s milk allergy 
increased with increasing number of child’s antibiotics used from 
birth to diagnosis [ 14 ]. In a recent review Marrs et al. conducted a 
systematic review to test the hypothesis that microbial exposure 
can modulate the risk of developing FA and concluded that factors 
infl uencing microbial exposure, such as mode of delivery, rural 
animal exposure, diet, childhood infections, immunizations, and 
antibiotic use, may be partly responsible for rising FA burden, but 
further prospective studies using double-blind placebo controlled 
food challenges as an outcome are required [ 6 ]. 
3  Allergen-Specifi c and Non-allergen-specifi c Therapies 
 Based on our current knowledge of the immune basis of food 
allergy, therapeutic strategies have focused on reducing levels of 
allergen-specifi c IgE, enhancing levels of allergen-specifi c IgG or 
IgA, suppressing Th2 effector cells, or enhancing  regulatory T cells 
through a variety of allergen-specifi c and allergen non-specifi c 
strategies [ 15 ]. 
 In the past 10 years allergen  immunother apy by the oral, sublin-
gual, or epicutaneous routes has been the subject of intense 
research focus. Results are promising when desensitization, defi ned 
as protection from food-induced reactions while receiving therapy, 
is used as a primary outcome [ 16 – 18 ]. However, there is a lack of 
clarity about safety and long-term effi cacy of the  treatment . Adverse 
reactions to oral immunotherapy are not uncommon, and a signifi -
cant number of subjects experience adverse reactions of suffi cient 
severity or persistence to prevent continuation of immunotherapy. 
The most successful trials report that at least half of patients who 
begin immunotherapy do not achieve successful long term  toler-
ance [ 19 ,  20 ]. Preclinical research on food allergy immunotherapy 
safety has primarily focused on modifi cations to allergen structure 
to reduce IgE binding. Allergens can be modifi ed through heating, 
which denatures the proteins and destroys conformational epitopes; 
digestion, which forms peptides that are too short to cross- link IgE 
but maintain T cell epitopes would have the capacity to generate 
3.1  Allergen-Specifi c 
Therapies
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T cell-mediated immunomodulation; and chemical modifi cation, 
for example glycosylation of allergens can signifi cantly modify their 
immunogenicity and allergenicity [ 15 ]. 
 Some allergens can be modifi ed simply through heating. Heating 
denatures the proteins and destroys conformational epitopes, and 
there are also matrix effects that infl uence digestion and absorption 
of the allergens. Milk- or egg-allergic children enrolled in interven-
tion studies in which they incorporated extensively heated milk or 
egg into the diet outgrew their unheated egg or milk allergy more 
quickly than a control group that received standard of care [ 21 ,  22 ], 
and this inclusion of milk or egg was associated with changes in 
immune parameters consistent with an immunotherapeutic 
response (elevation in IgG4, decreases in allergen-specifi c IgE). 
Heating to reduce allergenicity is applicable to egg or milk, but not 
to antigens such as peanut where high heat increases allergenicity 
rather than reducing it. Allergens can be also modifi ed through 
digestion, which forms peptides that are too short to cross-link IgE 
but maintain T cell epitopes would have the capacity to generate T 
cell-mediated immunomodulation. Immuno-dominant peptides in 
the peanut allergens Ara h 1 [ 23 ] and Ara h 2 [ 24 ] have recently 
been identifi ed with the goal of developing peptide  immunother apy. 
In addition to digestion and heating, allergens can be modifi ed 
by chemical modifi cation. Glycosylation of allergens can signifi -
cantly modify their immunogenicity and allergenicity. Carbohydrate 
structures can both promote and suppress allergenicity. There is 
evidence that exposure of some allergens to high heat can enhance 
allergenicity through glycation, which allows for recognition of the 
allergens by pattern recognition receptors on antigen-presenting 
cells [ 25 ,  26 ]. But glycosylation can also result in enhanced 
immune  tolerance . At preclinical level, research on improvements 
in effi cacy of food allergy immunotherapy is focused on adjuvant 
optimization. Adjuvants that amplify either a Th1 response or a 
regulatory response may be necessary to suffi ciently suppress the 
Th2-skewed immunity that drives the allergic response to foods. 
Many of these adjuvants are of microbial origin and range from 
whole heat-killed bacteria to co-administered purifi ed microbial 
products to fusion proteins incorporating allergen and adjuvant in 
one. By binding to innate pattern recognition receptors on anti-
gen-presenting cells, these adjuvants are thought to drive the T cell 
response away from a Th2 response. Adjuvants not only modify 
the nature of the immune response, but amplify the response such 
that signifi cantly lower doses of allergen may be suffi cient for an 
immunotherapeutic effect. The immune basis of tolerance induced 
by allergen immunotherapy for food allergy is still the subject of 
intensive research; immunotherapy is associated with elevations in 
allergen-specifi c IgG4 and IgA, and reductions in diversity of 
epitopes recognized by allergen-specifi c IgE, skin prick test wheal 
3.2  Modifi ed 
Allergens 
and Adjuvants 
for Allergen 
Immunotherapy
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size, allergen-induced basophil activation, and allergen- induced 
Th2 cytokine production [ 27 – 29 ]. These parameters are associated 
with  immunother apy, but so far there have been no biomarkers 
described that successfully predict tolerance versus desensitization 
in response to immunotherapy. 
 Therapies that are not allergen specifi c are especially attractive 
because many patients have multiple food allergies and allergen 
 immunother apy with specialized allergen adjuvant constructs may 
be of limited value in these patients. In this fi eld, there is a signifi -
cant interest in probiotics and the possibility of manipulating the 
microbiome for therapeutic purposes. Recently, we demonstrated 
that  treatment of cow’s milk allergy (CMA) infants with an exten-
sively hydrolyzed casein formula (eHCF) supplemented with the 
probiotic  Lactobacillus rhamnosus GG (LGG) accelerates oral  tol-
erance acquisition to cow’s milk [ 30 ,  31 ]. Subsequently, we tested 
the hypothesis that eHCF plus LGG induced effect on oral toler-
ance thanks to an infl uence of this dietary intervention on the 
composition of the gut microbiota (Fig.  1 ). High-throughput 
sequencing technology (16S rRNA-based sequence analysis) was 
used to compare fecal samples from newly diagnosed CMA infants, 
collected before and after treatment with eHCF plus LGG, to 
3.3  Allergen- 
Nonspecifi c Therapies
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 Fig. 1  A schematic representation of the potential mechanisms of action of eHCF 
plus LGG in children with cow’s milk allergy. Treatment with EHCF plus LGG 
expanded gut microbiota populations associated with immunoregulatory effects 
and increased butyrate production at intestinal level. Gut microbiota is a crucial 
factor for food oral tolerance and it regulates an appropriate balance between 
immune effectors and regulatory pathways. Short chain fatty acids (SCFAs) such 
as propionate, acetate and butyrate are gut microbiota-derived bacterial fermen-
tation products that selectively expand  Tregs in the large intestine. These SCFAs 
stimulate the expansion and immune-suppressive properties of Tregs, such as 
the production of IL-10. Moreover, the specifi c immunomodulatory effect of eHCF 
plus LGG may be due to small specifi c peptides, which are absent in other 
formulas 
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those obtained from controls. Treatment with eHCF plus LGG 
expanded gut microbiota populations associated with immunoreg-
ulatory effects. Otherwise healthy infants with CMA were given 
eHCFs ( n = 55), eHCF with LGG ( n = 71), hydrolyzed rice for-
mula ( n = 46), soy formula ( n = 55), or amino acid-based formula 
( n = 33), and oral food challenges were performed after 12 months 
to assess acquisition of tolerance. The rate of tolerance after 12 
months was signifi cantly higher ( p < 0.05) in the groups receiving 
eHCF (43.6 %) or eHCF plus LGG (78.9 %) compared with the 
other groups: hydrolyzed rice formula (32.6 %), soy formula (23.6 %), 
and amino acid-based formula (18.2 %). Our in vitro and in vivo 
data suggest that eHCF containing LGG promotes oral tolerance 
through a combination of different mechanisms. These fi ndings 
suggest a potential innovative therapeutic approach for children 
affected by FA.
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